Remove Doctors Remove Long-Term Care Facilities Remove Virus
article thumbnail

FDA Advisory Panel Says Yes to Pfizer’s COVID Vaccine

The Pharma Data

First in line are health care personnel and residents and staff of long-term care facilities, according to earlier recommendations released by the CDC panel. Doctors say this reflects India’s younger and leaner population. When you don’t have that capacity, that means people will die.”

Vaccine 52
article thumbnail

Biden Will Ask Americans to Wear Masks for 100 Days

The Pharma Data

And I think we’ll see a significant reduction” in the virus, Biden told CNN. The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities.

Vaccine 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CDC Director Warns of Dire Winter Ahead for COVID Hospitalizations, Deaths

The Pharma Data

Though coronavirus cases have exploded recently, with new infections topping 1 million a week, a far smaller proportion of people who get the virus now are dying from it. Doctors say this reflects India’s younger and leaner population. Things are not shut down.” ” One positive? percent in April to 1.9

article thumbnail

Britain Approves Emergency Use of Pfizer’s COVID Vaccine

The Pharma Data

The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities. Hospitalizations reach record high.

Vaccine 40
article thumbnail

Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

The Pharma Data

“This emergency authorization allows us to make bamlanivimab available as a COVID-19 treatment for recently diagnosed, high-risk patients – adding a valuable tool for doctors fighting the now-increasing burden of this global pandemic,” said David A. Ricks, Lilly’s chairman and CEO.

article thumbnail

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

Lilly has received feedback from front-line nurses and doctors administering these infusions regarding the complexity and time requirements for preparation and administration. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19.